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Recent evidence indicates that a single dose of mRNA-based vaccines 
produce similar immune responses in people with evidence of past 
infection compared with two doses in immunologically naive 
individuals. For COVID-19 vaccines with two dose regimens, point-of-
care antibody testing for prior infection when administering the first 
dose could enable expanded vaccine access in a cost-effective 
manner. Generally, antibody tests with sensitivity and specificity well 
below that typically accepted for product licensure would still enable 
expanded vaccine coverage, though to be cost-beneficial total test 
cost (i.e. procurement and administration) needs to be less than 
roughly a third of total vaccine dose cost. For highly sensitive (90%) 
and specific (99%) tests, coverage could be expanded by more than 
33%. Tests with the appropriate performance characteristics are 
plausible, though likely need setting specific tailoring.
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Introduction
Many countries have experienced high SARS-CoV-2 infec-
tion attack rates and currently have limited vaccine supplies. 
For example, countries participating in the CO-VAX facil-
ity expect to receive vaccine coverage for only 20% of their 
populations1, with any additional coverage depending on 
availability and cost. However, recent evidence indicates that 
a single dose of the mRNA-based vaccines (e.g. the Pfizer or 
Moderna products) produce immune responses in people with 
evidence of past infection (i.e. seropositive) that are at least 
comparable to the response elicited by two doses in immunologi-
cally naive individuals2–6. 
If effects observed in these studies are validated, the use of a 
point-of-care antibody test when administering the first dose 
could allow for more efficient use of available vaccine doses. 
This benefit depends on test performance, cost, and the 
seroprevalence in the population being vaccinated. Intuitively, 
the advantage will increase with greater seroprevalence 
because there is more opportunity to reallocate the second dose. 
To be a better option than buying more doses, administering a 
test should cost less than a single vaccine dose, but how much 
less will depend on test specificity (to avoid giving too few 
doses) and sensitivity (to benefit from reallocating doses), as 
well as seroprevalence. Several rapid, point-of-care antibody 
tests7–10 are available that may ultimately be able meet these 
requirements; however, further testing and development 
may be needed to validate and tailor tests for use in different 
contexts11–13. Data to evaluate vaccine effectiveness for a sin-
gle dose conditional on antibody testing could be collected 
in countries pursuing a delayed second dose scheme, like the 
United Kingdom.
Methods
Calculations performed in R (4.0.3)14, with visualizations 
prepared using data.table15, ggplot216, and patchwork17.
Coverage with testing
To analyze the direct benefit of this dose-sparing approach, 
we conservatively assume seronegative individuals are fully 
vaccinated (i.e. protected at the efficacy of the vaccine) only 
after two doses, and seropositive individuals after one dose. 
With a test, most seropositive individuals get one dose instead 
of two, freeing up doses to protect more people. Given a fixed 
supply, the number of additional people that could be pro-
tected depends on both test performance and the seroprevalence 
in the population of interest.
To evaluate this relationship, we model the population as hav-
ing a homogeneous distribution of potentially test-detectable 
prior SARS-CoV-2 infection, characterized by a population-level 
seroprevalance, ρ
+
= 1 − ρ
−
. We model a test that is character-
ized by sensitivity (the true-positive rate, the complement of 
the false negative rate TPR = 1 − FNR), and specificity (the 
true-negative rate, the complement of the false positive rate 
TNR = 1 − FPR). For practical applications, these values will 
be entangled, since we know that e.g. SARS-CoV-2 antibody 
responses decline with time18.
If we assume, pessimistically, that a single dose is not protec-
tive when given to seronegative individuals, then in our model 
the people protected per dose (PPD) is:
PPD 0.5 (TNR FNR ) 1 TRP 0 FRP* * *ρ ρ ρ ρ= + + +− + + −
which we can re-arrange in terms of complementary parameters:
          
2PPD (TNR(1 ) (1 TRP) ) 2TRP
TNR TNR TRP 2TRP
TNR TNR TRP
TNR (1 TRP TNR)
ρ ρ ρ




+ + + +
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          (1)
Recall that without testing, two doses are required for vaccine 
immunity, i.e. PPD = 0.5. This corresponds to the situation 
where TNR = 1 (because the “test” is simply that everyone 
gets two doses) and TPR = 0 (because no one gets a single 
dose). Relative to this baseline, the relative change in PPD 
due to introducing testing is:











= + + − −
∼                  (2)
Assuming a single dose is non-protective in seronegative 
individuals helps ensure that the model represents the mini-
mal benefit, and thus decisions continue to be beneficial even 
after accommodating real-world factors that are impractical to 
model. This limiting assumption implies that introducing 
testing can reduce the number of people effectively vaccinated. 
As practical matter, this is only a problem with extreme 
combinations of sero-prevalence and test performance, which 
are not generally relevant for the settings where this scheme 
is worth considering. The constraining relation is Δ
PPD 
> 0 or 
TNR + ρ
+
 (1 + TPR − TNR) > 1. For example, in a popula-
tion with 20% seroprevalence, using a test with low specificity, 
50%, would be detrimental even with a perfectly sensitive 
test.
Costs
Though testing will increase the overall cost of the vaccine 
program (relative to a fixed number of available vaccine doses), 
decision-makers should consider the cost per fully vacci-
nated person. One way to make that decision is to estimate 
which is the less expensive way to expand coverage: expanding 
the supply by buying more vaccine doses or more efficiently 
using the existing supply with testing. We model the total cost 
per vaccine dose of V (i.e. production, logistics, and admin-
istration) and total cost per test of T. On the margin, imagine 
purchasing one more protected person: that can be accom-
plished for 2V (i.e. two doses to get a fully vaccinated 
person without testing) or for some expected number of tests, 
nT, to allow re-allocation of unnecessary second doses from 
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seropositive recipients. Restricting our consideration to situ-
ations with positive Δ
PPD
, we can think about the relationship 
between n and Δ
PPD
.
If testing increases the PPD by e.g. 10%, then using 20 tests (on 
average) would add another fully immunized individual. Even 
in a situation where the test is perfect and everyone is sero-
positive (i.e. testing increases PPD by 100%), two tests are 
still required: one to free up the second dose from an individ-
ual and one to confirm that the next recipient in line only needs 






using tests is preferred when







≤ → ≤ Δ
Δ
                             (3)
Results
Expanded coverage
Using Equation 2, we find that using a pre-vaccination anti-
body testing program could substantially expand vaccine cov-
erage in populations with relatively high seroprevalence. 
Rearranging Equation 2 and considering a high specificity 
(99% or TNR = 0.99) test, only moderate seroprevalence and 
sensitivity are required to observe gains:
                                (0.01 TPR) 0.01ρ+ + >                                 (4)
With this high specificity and a 40% seroprevalence (ρ
+
 = 0.4) 
in the population of interest, only TPR > 0.015 (or sensitiv-
ity of 1.5%) is necessary to expand coverage, though of course 
such low performance does not expand coverage much. How-
ever, a test with sensitivity more typical of licensed medical 
assays (90%) would expand coverage by 35% (e.g. increas-
ing a COVAX-like coverage of 20% to 27%). Given that the 
test is not needed to determine treatment, but rather more 
efficiently allocate doses, lower sensitivity (e.g. 70%) might 
be substantially less expensive, and even that lower per-
formance would expand coverage by 27% (e.g. increasing a 
COVAX-like coverage of 20% to 25%). In each of the three 
dimensions, coverage gains increase linearly: higher sero-
prevalence means more opportunity to reallocate doses, higher 
sensitivity means taking better advantage of that opportu-
nity, and higher specificity decreases the (assumed) loss of 
protection. Figure 1A shows this trend for seroprevalence 
(moving left to right on plot) and sensitivity (shifting from 
lower to higher trend lines).
Paying for testing versus more doses
Similar to expanding coverage, using Equation 3, we find 
that regions with relatively high seroprevalence could more 
effectively expand coverage with antibody testing than addi-
tional doses with a relatively high threshold for test cost. Per 
Equation 3, the cost threshold is identical to the coverage 
expansion, and as such also increases linearly with seropreva-
lence and test performance. Figure 1B shows this trend for 
Figure 1. Example benefits of testing. A) Assuming roughly 20% 
of the population (light grey region) could be vaccinated without 
any testing: with a highly specific test (99%), testing can expand 
the percentage covered by increasing amounts depending on 
seroprevalence and test sensitivity (light blue: 70% sensitive, dark 
blue: 90% sensitivity). While many individuals still go unvaccinated 
(white background), further incremental vaccine supply would 
result in similarly extended coverage under pre-vaccination testing 
approach. B) Testing can also expand the vaccinated fraction for 
lower costs, again depending on the vaccine-eligible population’s 
seroprevalence and the test’s performance. For a highly specific 
test, and relatively high seroprevalence, e.g. 40%, a test that is 
less than 27% (if >70% sensitive) to 35% (if >90% sensitive) the 
cost of a vaccine dose is a cheaper way to expand coverage than 
buying more doses of vaccine. The cost advantage of testing 
grows with increasing seroprevalence and test performance.
seroprevalence (moving left to right on plot) and sensitivity 
(shifting from lower to higher trend lines).
Recalling the high seroprevalence (40%), high specificity 
(99%), and high sensitivity (90%) scenario, the cost thresh-
old would be 35% of the cost of vaccination. Considering a 
per dose cost of roughly 15 USD (a rough direct price for the 
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mRNA vaccines19, but ignoring the additional administra-
tion and logistics costs), a test that cost around 5 USD or less 
would be a better investment to expand coverage. Even at a 
lower sensitivity (70%), the cost threshold remains plausible at 
4 USD or less per test.
Discussion and conclusions
Where a pre-vaccination antibody testing programme is imple-
mented, vaccine administration could be adapted to include 
a rapid, point-of-care antibody test before the first dose. The 
test result could be delivered at the end of the normal monitor-
ing period for severe acute reactions in recipients, allowing 
them to be advised whether they need a follow-up dose 
based on their test result. For tests with imperfect specifi-
city, some individuals with no past infection history would 
only receive a single dose; for our analysis, we conserva-
tively assume these people get no protection, though studies 
indicate at least short-term protection2. Other studies have 
suggested that past exposure alone is sufficiently protective, 
and that testing could be used to administer vaccines only to 
seronegative individuals20. While theoretically plausible, such 
an approach seems practically and politically untenable, could 
exacerbate existing inequity in COVID-19 health burdens, 
and does not account for potential effects like waning immu-
nity or immune escape variants where a single dose may boost 
protection3,6.
We have framed this analysis in terms of a population of inter-
est. While that population could be an entire country, it could 
likewise be a sub-national region and/or a particular age or 
employment group. The pre-vaccination testing approach is 
most beneficial for populations with high prior burden where 
there is still high risk of infection, but improperly communi-
cated could lead to the perception of these groups receiving 
inferior treatment and further exacerbating health inequities. 
While increased vaccine availability or more globally equi-
table distribution would reduce the need for dose-sparing 
methods, pragmatic solutions to expand coverage like testing 
may enable more efficient use in the current vaccine context. 
Indeed, approaches like this could be adopted in higher-income 
settings, where testing may require less calibration and other 
infrastructure advantages could offset the costs, thus freeing 
up vaccine supply globally.
In this analysis, we have tried to offer a conservative estimate 
of the potential benefits of using testing. We have focused on the 
directly protected individuals and the direct costs, but expand-
ing vaccination could also increase indirect protection by 
reducing transmission broadly21. Likewise, expanded vaccina-
tion could reduce the incidence of severe disease and associ-
ated costs and consumption of health service resources. We 
expect that a more sophisticated model incorporating these kinds 
of effects will predict higher testing benefits, though there are 
additional nuances that would dampen returns (e.g. account-
ing for prioritization of older populations who have high dis-
ease risk but likely lower past exposure rates). Given that our 
approach indicates substantial potential benefits despite being 
conservative, we recommend further development of rapid, 
point-of-care antibody testing and vaccine effectiveness stud-
ies to verify protection of seropositive individuals after single 
doses.
Data availability
All data underlying the results are available as part of the article 
and no additional source data are required.
Code availability
Source code available from https://github.com/cmmid/covidTest-
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